{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:53:55Z","timestamp":1790661235345,"version":"4.1.0"},"reference-count":50,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy, safety, and role of live biotherapeutic products (LBPs) in the prevention of recurrent Clostridioides difficile infection (rCDI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar (through February 2024) with search terms RBX2660, SER-109, and fecal microbiota. Other resources included abstracts presented at recent conferences, national clinical practice guidelines, and manufacturers\u2019 websites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant studies, trial updates, conference abstracts, and guidelines in the English language were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Two LBPs were recently approved by the Food and Drug Administration for the prevention of recurrence in adults following antibiotic treatment for rCDI. Fecal microbiota, live-jslm is administered rectally as a retention enema, whereas fecal microbiota spores, live-brpk is given orally after bowel preparation. Several phase 2 and phase 3 clinical trials have established the safety and efficacy of these LBPs in reducing rates of rCDI compared with placebo. Patients with severe immunosuppression and those with inflammatory bowel disease were largely excluded from these trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:<\/jats:title>\n                    <jats:p>Live biotherapeutic products offer a similar mechanism to conventional fecal microbiota transplant (FMT) in preventing rCDI through microbiota restoration. The primary advantages of LBPs over FMT are their standardized composition and donor stool screening processes for transmissible pathogens. Bezlotoxumab is also available for the prevention of Clostridioides difficile infection; however, there are no clinical data available to compare the efficacy of LBPs with bezlotoxumab, and the benefit of simultaneous use of these preventative therapies is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Live biotherapeutic products provide a safe and effective option for the prevention of rCDI and represent an improvement over conventional FMT. Additional studies are needed to further determine their place in therapy relative to bezlotoxumab and in the setting of immunosuppression and inflammatory bowel disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241239685","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T08:07:53Z","timestamp":1711613273000},"page":"1204-1217","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Live Biotherapeutic Products for the Prevention of Recurrent\n                    <i>Clostridioides difficile<\/i>\n                    Infection"],"prefix":"10.1177","volume":"58","author":[{"given":"Natasha N.","family":"Pettit","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UChicago Medicine, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy M.","family":"Shaeer","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics & Clinical Research, University of South Florida Taneja College of Pharmacy, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Palm Beach Atlantic University Lloyd L. Gregory School of Pharmacy, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"bibr1-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08096-0"},{"key":"bibr2-10600280241239685","doi-asserted-by":"publisher","DOI":"10.15620\/cdc:82532"},{"key":"bibr3-10600280241239685","unstructured":"Centers for Disease Control and Prevention. Emerging infections program. Healthcare-associated infections-community interface report.\n                      Clostridioides difficile\n                      infection surveillance, 2021. Accessed March 11, 2024. https:\/\/www.cdc.gov\/hai\/eip\/Annual-CDI-Report-2021.html"},{"key":"bibr4-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12046"},{"key":"bibr5-10600280241239685","unstructured":"Rebyota (fecal microbiota, live-jslm). Rebiotix; 2022."},{"key":"bibr6-10600280241239685","unstructured":"Vowst (fecal microbiota spores, live-brpk). Seres Therapeutics; 2023."},{"key":"bibr7-10600280241239685","unstructured":"Vedanta Biosciences. VE303. Accessed January 27, 2024. https:\/\/www.vedantabio.com\/pipeline\/ve303"},{"key":"bibr8-10600280241239685","unstructured":"US Food & Drug Administration. Fecal microbiota for transplantation: safety alert\u2014risk of serious adverse events likely due to transmission of pathogenic organisms. Published April 7, 2020. Accessed January 27, 2024. https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission"},{"key":"bibr9-10600280241239685","unstructured":"US Food & Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to SARS-CoV-2 and COVID-19. Published March 23, 2020. Accessed January 27, 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections"},{"key":"bibr10-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01797-x"},{"key":"bibr11-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106516"},{"key":"bibr12-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.55758"},{"key":"bibr13-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab718"},{"key":"bibr14-10600280241239685","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001278"},{"key":"bibr15-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.01.008"},{"key":"bibr16-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07256-y"},{"key":"bibr17-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110591"},{"key":"bibr18-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ938"},{"key":"bibr19-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy259"},{"key":"bibr20-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00744-3"},{"key":"bibr21-10600280241239685","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000857168.31201.9f"},{"key":"bibr22-10600280241239685","unstructured":"Rebiotix, Inc. Microbiota restoration therapy for recurrent\n                      Clostridium difficile\n                      infection (PUNCH CD3-OLS) (CD3-OLS). Clinical Trials.gov Identifier: NCT03931941. Published April 10, 2023. Accessed January 27, 2024. https:\/\/clinicaltrials.gov\/study\/nct03931941"},{"key":"bibr23-10600280241239685","unstructured":"US Food & Drug Administration. RBX2660 (fecal microbiota, live\u2014jslm) clinical review memorandum. Published November 20, 2022. Accessed January 27, 2024. https:\/\/www.fda.gov\/media\/168274\/download"},{"key":"bibr24-10600280241239685","unstructured":"Seres Therapeutics. SER-109 versus placebo to prevent recurrent\n                      Clostridium difficile\n                      infection (SERES-004 ECOSPOR). Clinical Trials.gov Identifier: NCT 02437487. Published July 26, 2018. Accessed January 27, 2024. https:\/\/clinicaltrials.gov\/study\/nct02437487"},{"key":"bibr25-10600280241239685","unstructured":"US Food & Drug Administration. SER-109 (fecal microbiota spores, live-brpk) clinical review memorandum. Published April 26, 2023. Accessed January 27, 2024. https:\/\/www.fda.gov\/media\/168274\/download"},{"key":"bibr26-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa387"},{"key":"bibr27-10600280241239685","author":"Harvey A","year":"2022","journal-title":"Making a difference in infectious diseases annual meeting"},{"key":"bibr28-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad171"},{"key":"bibr29-10600280241239685","volume-title":"American College of Clinical Pharmacy annual meeting","author":"Gonzales-Luna AJ"},{"key":"bibr30-10600280241239685","volume-title":"Society for Healthcare Epidemiology of America Spring Meeting","author":"Sims M"},{"key":"bibr31-10600280241239685","volume-title":"Making a Difference in Infectious Diseases annual meeting","author":"Harvey A"},{"key":"bibr32-10600280241239685","volume-title":"Society for Healthcare Epidemiology of America Spring Meeting","author":"Sims M"},{"key":"bibr33-10600280241239685","unstructured":"Rebyota. For healthcare professionals. Accessed January 27, 2024. https:\/\/www.rebyotahcp.com\/"},{"key":"bibr34-10600280241239685","unstructured":"Micromedex. Rebyota. Lexi-Comp. Published 2024. Accessed January 27, 2024. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/"},{"key":"bibr35-10600280241239685","unstructured":"Micromedex. Vowst. Lexi-Comp. Published 2024. Accessed January 27, 2024. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/"},{"key":"bibr36-10600280241239685","unstructured":"Rebyota. Rebyota support & resources. Accessed January 27, 2024. https:\/\/www.rebyota.com\/rebyota-support-resources\/"},{"key":"bibr37-10600280241239685","unstructured":"Vowst. Savings and support. Accessed January 27, 2024. https:\/\/www.vowst.com\/savings-and-support"},{"key":"bibr38-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad383"},{"key":"bibr39-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.53570"},{"key":"bibr40-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02505-1"},{"key":"bibr41-10600280241239685","unstructured":"Zinplava (bezlotoxumab). Merck Sharp & Dohme, LLC. May 2023."},{"key":"bibr42-10600280241239685","doi-asserted-by":"publisher","DOI":"10.4161\/gmic.1.1.10768"},{"key":"bibr43-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.02897-14"},{"key":"bibr44-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602615"},{"key":"bibr45-10600280241239685","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11091211"},{"key":"bibr46-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa114"},{"key":"bibr47-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100642"},{"key":"bibr48-10600280241239685","unstructured":"US Food & Drug Administration. Safety alert regarding use of fecal microbiota for transplantation and additional safety protections pertaining to monkeypox virus. Published August 22, 2022. Accessed January 27, 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/safety-alert-regarding-use-fecal-microbiota-transplantation-and-additional-safety-protections-0"},{"key":"bibr49-10600280241239685","unstructured":"Ferring Pharmaceuticals. Press release 2023. Four analyses of data for REBYOTA\n                      TM\n                      (fecal microbiota, live-jslm), the first FDA-approved microbiome-based treatment for the prevention of recurrent\n                      C. difficile\n                      infection, presented at DDW 2023. Published May 8, 2023. Accessed January 27, 2023. https:\/\/www.ferring.com\/four-analyses-of-data-for-rebyota-fecal-microbiota-live-jslm-the-first-fda-approved-microbiome-based-treatment-for-the-prevention-of-recurrent-c-difficile-infection-presented\/"},{"key":"bibr50-10600280241239685","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad448"}],"updated-by":[{"DOI":"10.1177\/10600280241310646","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000}}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241239685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241239685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241239685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:38Z","timestamp":1777374818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241239685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/10600280241239685"],"URL":"https:\/\/doi.org\/10.1177\/10600280241239685","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}